Cargando…

Identification & characterization of leucine-rich repeat kinase 2 & parkin RBR E3 ubiquitin protein ligase variants in patients with Parkinson's disease

BACKGROUND & OBJECTIVES: Parkinson's disease (PD) is a motor disorder that affects movement. More than 24 loci and 28 associated genes have been identified to be associated with this disease. The present study accounts for the contribution of two candidates, leucine-rich repeat kinase 2 (LR...

Descripción completa

Detalles Bibliográficos
Autores principales: Halder, Tamali, Verma, Shiv Prakash, Raj, Janak, Pandey, Sharad, Singh, Ranjeet Kumar, Sharma, Vivek, Joshi, Deepika, Das, Parimal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157902/
https://www.ncbi.nlm.nih.gov/pubmed/33707392
http://dx.doi.org/10.4103/ijmr.IJMR_730_18
_version_ 1783699782723698688
author Halder, Tamali
Verma, Shiv Prakash
Raj, Janak
Pandey, Sharad
Singh, Ranjeet Kumar
Sharma, Vivek
Joshi, Deepika
Das, Parimal
author_facet Halder, Tamali
Verma, Shiv Prakash
Raj, Janak
Pandey, Sharad
Singh, Ranjeet Kumar
Sharma, Vivek
Joshi, Deepika
Das, Parimal
author_sort Halder, Tamali
collection PubMed
description BACKGROUND & OBJECTIVES: Parkinson's disease (PD) is a motor disorder that affects movement. More than 24 loci and 28 associated genes have been identified to be associated with this disease. The present study accounts for the contribution of two candidates, leucine-rich repeat kinase 2 (LRRK2) and parkin RBR E3 ubiquitin protein ligase (PRKN) in the PD patients, and their characterization in silico and in vitro. METHODS: A total of 145 sporadic PD cases and 120 ethnically matched healthy controls were enrolled with their informed consent. Mutation screening was performed by direct DNA sequencing of the targeted exons of LRRK2 and all exons flanking introns of PRKN. The effect of the pathogenic PRKN variants on a drug (MG-132) induced loss of mitochondrial membrane potential (△ΨM) was measured by a fluorescent dye tetramethylrhodamine methyl ester (TMRM). RESULTS: Twelve and 20 genetic variants were identified in LRRK2 and PRKN, respectively. Interestingly, five out of seven exonic LRRK2 variants were synonymous. Further assessment in controls confirmed the rarity of two such p.Y1527 and p.V1615. Among the pathogenic missense variations (as predicted in silico) in PRKN, two were selected (p.R42H and p.A82E) for their functional study in vitro, which revealed the reduced fluorescence intensity of TMRM as compared to wild type, in case of p.R42H but not the other. INTERPRETATION & CONCLUSIONS: About 6.2 per cent of the cases (9/145) in the studied patient cohort were found to carry pathogenic (as predicted in silico) missense variations in PRKN in heterozygous condition but not in case of LRRK2 which was rare. The presence of two rare synonymous variants of LRRK2 (p.Y1527 and p.V1615) may support the phenomenon of codon bias. Functional characterization of selected PRKN variations revealed p.R42H to cause disruption of mitochondrial membrane potential (△ΨM) rendering cells more susceptible to cellular stress.
format Online
Article
Text
id pubmed-8157902
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-81579022021-06-04 Identification & characterization of leucine-rich repeat kinase 2 & parkin RBR E3 ubiquitin protein ligase variants in patients with Parkinson's disease Halder, Tamali Verma, Shiv Prakash Raj, Janak Pandey, Sharad Singh, Ranjeet Kumar Sharma, Vivek Joshi, Deepika Das, Parimal Indian J Med Res Original Article BACKGROUND & OBJECTIVES: Parkinson's disease (PD) is a motor disorder that affects movement. More than 24 loci and 28 associated genes have been identified to be associated with this disease. The present study accounts for the contribution of two candidates, leucine-rich repeat kinase 2 (LRRK2) and parkin RBR E3 ubiquitin protein ligase (PRKN) in the PD patients, and their characterization in silico and in vitro. METHODS: A total of 145 sporadic PD cases and 120 ethnically matched healthy controls were enrolled with their informed consent. Mutation screening was performed by direct DNA sequencing of the targeted exons of LRRK2 and all exons flanking introns of PRKN. The effect of the pathogenic PRKN variants on a drug (MG-132) induced loss of mitochondrial membrane potential (△ΨM) was measured by a fluorescent dye tetramethylrhodamine methyl ester (TMRM). RESULTS: Twelve and 20 genetic variants were identified in LRRK2 and PRKN, respectively. Interestingly, five out of seven exonic LRRK2 variants were synonymous. Further assessment in controls confirmed the rarity of two such p.Y1527 and p.V1615. Among the pathogenic missense variations (as predicted in silico) in PRKN, two were selected (p.R42H and p.A82E) for their functional study in vitro, which revealed the reduced fluorescence intensity of TMRM as compared to wild type, in case of p.R42H but not the other. INTERPRETATION & CONCLUSIONS: About 6.2 per cent of the cases (9/145) in the studied patient cohort were found to carry pathogenic (as predicted in silico) missense variations in PRKN in heterozygous condition but not in case of LRRK2 which was rare. The presence of two rare synonymous variants of LRRK2 (p.Y1527 and p.V1615) may support the phenomenon of codon bias. Functional characterization of selected PRKN variations revealed p.R42H to cause disruption of mitochondrial membrane potential (△ΨM) rendering cells more susceptible to cellular stress. Wolters Kluwer - Medknow 2020-11 /pmc/articles/PMC8157902/ /pubmed/33707392 http://dx.doi.org/10.4103/ijmr.IJMR_730_18 Text en Copyright: © 2021 Indian Journal of Medical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Halder, Tamali
Verma, Shiv Prakash
Raj, Janak
Pandey, Sharad
Singh, Ranjeet Kumar
Sharma, Vivek
Joshi, Deepika
Das, Parimal
Identification & characterization of leucine-rich repeat kinase 2 & parkin RBR E3 ubiquitin protein ligase variants in patients with Parkinson's disease
title Identification & characterization of leucine-rich repeat kinase 2 & parkin RBR E3 ubiquitin protein ligase variants in patients with Parkinson's disease
title_full Identification & characterization of leucine-rich repeat kinase 2 & parkin RBR E3 ubiquitin protein ligase variants in patients with Parkinson's disease
title_fullStr Identification & characterization of leucine-rich repeat kinase 2 & parkin RBR E3 ubiquitin protein ligase variants in patients with Parkinson's disease
title_full_unstemmed Identification & characterization of leucine-rich repeat kinase 2 & parkin RBR E3 ubiquitin protein ligase variants in patients with Parkinson's disease
title_short Identification & characterization of leucine-rich repeat kinase 2 & parkin RBR E3 ubiquitin protein ligase variants in patients with Parkinson's disease
title_sort identification & characterization of leucine-rich repeat kinase 2 & parkin rbr e3 ubiquitin protein ligase variants in patients with parkinson's disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157902/
https://www.ncbi.nlm.nih.gov/pubmed/33707392
http://dx.doi.org/10.4103/ijmr.IJMR_730_18
work_keys_str_mv AT haldertamali identificationcharacterizationofleucinerichrepeatkinase2parkinrbre3ubiquitinproteinligasevariantsinpatientswithparkinsonsdisease
AT vermashivprakash identificationcharacterizationofleucinerichrepeatkinase2parkinrbre3ubiquitinproteinligasevariantsinpatientswithparkinsonsdisease
AT rajjanak identificationcharacterizationofleucinerichrepeatkinase2parkinrbre3ubiquitinproteinligasevariantsinpatientswithparkinsonsdisease
AT pandeysharad identificationcharacterizationofleucinerichrepeatkinase2parkinrbre3ubiquitinproteinligasevariantsinpatientswithparkinsonsdisease
AT singhranjeetkumar identificationcharacterizationofleucinerichrepeatkinase2parkinrbre3ubiquitinproteinligasevariantsinpatientswithparkinsonsdisease
AT sharmavivek identificationcharacterizationofleucinerichrepeatkinase2parkinrbre3ubiquitinproteinligasevariantsinpatientswithparkinsonsdisease
AT joshideepika identificationcharacterizationofleucinerichrepeatkinase2parkinrbre3ubiquitinproteinligasevariantsinpatientswithparkinsonsdisease
AT dasparimal identificationcharacterizationofleucinerichrepeatkinase2parkinrbre3ubiquitinproteinligasevariantsinpatientswithparkinsonsdisease